However , there is no such license specifically for    because the underlying treatment was not patented by the N. C. I.so royalties will be minimal .Officials say the agency did not apply for a patent because the treatment was similar to what others had been developing .Also , at the time the treatment the underlying treatment created , in 2007 , immunotherapy was considered to have dim commercial prospects .